Calderasib + Oxaliplatin + Leucovorin/levofolinate calcium + 5-Fluorouracil + Cetuximab + Bevacizumab + Bevacizumab biosimilar

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Colon Adenocarcinoma

Conditions

Colon Adenocarcinoma, Rectal Adenocarcinoma

Trial Timeline

Jul 16, 2025 → Oct 27, 2030

NCT ID

NCT06997497

About Calderasib + Oxaliplatin + Leucovorin/levofolinate calcium + 5-Fluorouracil + Cetuximab + Bevacizumab + Bevacizumab biosimilar

Calderasib + Oxaliplatin + Leucovorin/levofolinate calcium + 5-Fluorouracil + Cetuximab + Bevacizumab + Bevacizumab biosimilar is a phase 3 stage product being developed by Merck for Colon Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06997497. Target conditions include Colon Adenocarcinoma, Rectal Adenocarcinoma.

What happened to similar drugs?

4 of 13 similar drugs in Colon Adenocarcinoma were approved

Approved (4) Terminated (5) Active (5)

🔄fospropofol disodiumEisaiPhase 3

❌AvelumabMerckPhase 3

🔄Systemic treatmentRochePhase 3

❌AZLI + PlaceboGilead SciencesPhase 3

🔄Isovorin + UFTPfizerPhase 3

✅Methylnaltrexone Bromide (MNTX) + PlaceboPfizerApproved

✅oxaliplatinSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06997497	Phase 3	Recruiting	Jul 16, 2025	Oct 27, 2030	Colon Adenocarcinoma

Competing Products

20 competing products in Colon Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
FOLFIRI + E7820	Eisai	Phase 1/2	24
fospropofol disodium	Eisai	Phase 3	40
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl	Eisai	Phase 2/3	38
fospropofol disodium	Eisai	Phase 2	27
fospropofol disodium	Eisai	Phase 2	35
Cetuximab + Irinotecan + IMC-A12 (cixutumumab)	Eli Lilly	Phase 2	27
Ramucirumab + Icrucumab + mFOLFOX-6	Eli Lilly	Phase 2	35
Vinorelbine Tartrate	Eli Lilly	Phase 2	35
Enzastaurin HCl	Eli Lilly	Phase 2	35
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	26
ULTRESA + PANCREAZE + CREON + ZENPEP + other non-sponsor pancreatic enzyme replacement therapy + PERTZYE	AbbVie	Pre-clinical	18
Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab	AstraZeneca	Phase 1	29
AZD0292	AstraZeneca	Phase 2	42
Cetuximab	Merck	Phase 2	27
Entereg + Entereg + placebo	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	27
Pembrolizumab + Ibrutinib	Merck	Phase 1/2	32
pembrolizumab + Poly-ICLC	Merck	Phase 1/2	32
MK-2206	Merck	Phase 2	27